Literature DB >> 21035331

Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors.

Sabina Pecchi1, Paul A Renhowe, Clarke Taylor, Susan Kaufman, Hanne Merritt, Marion Wiesmann, Kevin R Shoemaker, Mark S Knapp, Elizabeth Ornelas, Thomas F Hendrickson, Wendy Fantl, Charles F Voliva.   

Abstract

PI3 Kinases are a family of lipid kinases mediating numerous cell processes such as proliferation, migration, and differentiation. The PI3 kinase pathway is often de-regulated in cancer through PI3Kα overexpression, gene amplification, mutations, and PTEN phosphatase deletion. PI3K inhibitors represent therefore an attractive therapeutic modality for cancer treatment. Herein we describe a novel series of PI3K inhibitors sharing a pyrimidine core and showing significant potency against class I PI3 kinases in the biochemical assay and in cells. The discovery, synthesis and SAR of this chemotype are described.
Copyright © 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21035331     DOI: 10.1016/j.bmcl.2010.10.021

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  4 in total

1.  Identification of NVP-BKM120 as a Potent, Selective, Orally Bioavailable Class I PI3 Kinase Inhibitor for Treating Cancer.

Authors:  Matthew T Burger; Sabina Pecchi; Allan Wagman; Zhi-Jie Ni; Mark Knapp; Thomas Hendrickson; Gordana Atallah; Keith Pfister; Yanchen Zhang; Sarah Bartulis; Kelly Frazier; Simon Ng; Aaron Smith; Joelle Verhagen; Joshua Haznedar; Kay Huh; Ed Iwanowicz; Xiaohua Xin; Daniel Menezes; Hanne Merritt; Isabelle Lee; Marion Wiesmann; Susan Kaufman; Kenneth Crawford; Michael Chin; Dirksen Bussiere; Kevin Shoemaker; Isabel Zaror; Sauveur-Michel Maira; Charles F Voliva
Journal:  ACS Med Chem Lett       Date:  2011-08-26       Impact factor: 4.345

2.  Synthesis and in Vitro and in Vivo Evaluation of Phosphoinositide-3-kinase Inhibitors.

Authors:  Matthew T Burger; Mark Knapp; Allan Wagman; Zhi-Jie Ni; Thomas Hendrickson; Gordana Atallah; Yanchen Zhang; Kelly Frazier; Joelle Verhagen; Keith Pfister; Simon Ng; Aaron Smith; Sarah Bartulis; Hanne Merrit; Marion Weismann; Xiaohua Xin; Joshua Haznedar; Charles F Voliva; Ed Iwanowicz; Sabina Pecchi
Journal:  ACS Med Chem Lett       Date:  2010-10-13       Impact factor: 4.345

Review 3.  Recent syntheses of PI3K/Akt/mTOR signaling pathway inhibitors.

Authors:  Mark E Welker; George Kulik
Journal:  Bioorg Med Chem       Date:  2013-05-09       Impact factor: 3.641

Review 4.  Recent development of ATP-competitive small molecule phosphatidylinostitol-3-kinase inhibitors as anticancer agents.

Authors:  Yu Liu; Wen-Zhu Wan; Yan Li; Guan-Lian Zhou; Xin-Guang Liu
Journal:  Oncotarget       Date:  2017-01-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.